UCLA researchers have identified a population of senescent macrophages, termed “zombie” cells, that accumulate in aging tissues and contribute to fatty liver disease. These cells, which can constitute up to 80% of liver macrophages in older mice, release inflammatory signals that exacerbate liver damage. By selectively eliminating these senescent macrophages using the drug ABT-263, the study demonstrated a remarkable reversal of liver damage, with treated mice showing a significant reduction in liver size and overall body weight, despite continuing to consume a high-fat, high-cholesterol diet.

The implications of this research are profound, as it links macrophage senescence not only to fatty liver disease but potentially to broader mechanisms of aging and associated diseases. The study highlights how excess cholesterol can drive macrophages into a senescent state, suggesting that dietary factors may accelerate biological aging by promoting inflammation across multiple organ systems. This finding aligns with the geroscience hypothesis, which posits that common aging processes contribute to various age-related diseases, including atherosclerosis and Alzheimer’s disease.

Moving forward, the research underscores the need for the development of safer compounds that can target and eliminate senescent macrophages without the toxicity associated with ABT-263. This could pave the way for novel therapeutic strategies not only for fatty liver disease but also for a range of conditions linked to chronic inflammation and aging. Understanding the mechanisms behind macrophage senescence could fundamentally shift research paradigms and drug development timelines, focusing on inflammation as a pivotal target in the aging process.

Source: sciencedaily.com